MNST
59
2
OXY
46
2
KSS
47
-4
HBI
62
7
HSIC
53
2
RSG
67
2
KIM
51
4
HOG
29
-10
GIS
58
-2
LRCX
55
-6
HRB
85
-2
KR
59
10
L
63
3
PLD
58
10
IFF
69
13
CSX
39
-4
EA
47
-3
NTAP
72
10
ABT
45
-3
CHD
62
-2
MNST
59
2
OXY
46
2
KSS
47
-4
HBI
62
7
HSIC
53
2
RSG
67
2
KIM
51
4
HOG
29
-10
GIS
58
-2
LRCX
55
-6
HRB
85
-2
KR
59
10
L
63
3
PLD
58
10
IFF
69
13
CSX
39
-4
EA
47
-3
NTAP
72
10
ABT
45
-3
CHD
62
-2
Financhill
Back

SpringWorks Therapeutics 10K Form

Buy
64

SWTX
SpringWorks Therapeutics

Last Price:
44.86
Seasonality Move:
0.17%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SWTX News And Ratings

See the #1 stock for the next 7 days that we like better than SWTX

SWTX Financial Statistics

Sales & Book Value

Annual Sales: $5.45M
Cash Flow: $-79.51M
Price / Cash Flow: 0
Annual Sales: $7.66
Price / Book: 5.85

Profitability

EPS (TTM): -5.15000
Net Income (TTM): $-339.07M
Gross Margin: $5.03M
Return on Equity: -66.56%
Return on Assets: -57.73%

SpringWorks Therapeutics Earnings Forecast

Key SpringWorks Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for SWTX is 92.25%.
  • The Selling, General & Administrative Expenses for SWTX have been equal to 3,626.79% of Gross Profit Margin.
  • The Research & Development expenses have been 2,762.75% of Revenue.
  • The Net Earning history of SWTX is -5,968.50% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

SpringWorks Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SWTX
CUSIP: 85205L
Website: springworkstx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.85
Quick Ratio: 6.56

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SWTX Technical Analysis vs Fundamental Analysis

Buy
64
SpringWorks Therapeutics (SWTX) is a Buy

Is SpringWorks Therapeutics a Buy or a Sell?